Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRA Combined with Toripalimab and Chemotherapy in TNBC
NCT06636981Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Nov 2024
- Primary completion
- Sep 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tretinoin in triple-negative breast cancer (TNBC) (2 cohorts), sponsored by Fudan University. Primary endpoint: Objective Response Rate up to 2 years. Started Nov 2024; status: recruiting.
02
Drugs
tretinoin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06636981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06636981.